Effect of an Immune-Boosting, Antioxidant and Anti-Inflammatory Food Supplement in Hospitalized COVID-19 Patients: A Prospective Randomized Pilot Study

Author:

Reino-Gelardo Sandra1,Palop-Cervera Marta1,Aparisi-Valero Nieves2,Espinosa-San Miguel Ignacio1,Lozano-Rodríguez Noelia2,Llop-Furquet Gonzalo2,Sanchis-Artero Laura1ORCID,Cortés-Castell Ernesto3ORCID,Rizo-Baeza Mercedes4,Cortés-Rizo Xavier15ORCID

Affiliation:

1. Internal Medicine Department, Hospital of Sagunto, 46520 Sagunto, Spain

2. Clinical Analysis and Microbiology Service, Hospital of Sagunto, 46520 Sagunto, Spain

3. Department of Pharmacology, Pediatrics and Organic Chemistry, Miguel Hernández University, 03690 Alicante, Spain

4. Department of Nursing, University of Alicante, 03690 Alicante, Spain

5. Department of Medicine, Cardenal Herrera-CEU University, 46520 Valencia, Spain

Abstract

Background: COVID-19 disease is a serious global health problem. Few treatments have been shown to reduce mortality and accelerate time to recovery. The aim of this study was to evaluate the potential effect of a food supplement (probiotics, prebiotics, vitamin D, zinc and selenium) in patients admitted with COVID-19. Methods: A prospective randomized non-blinded clinical trial was conducted in a sample of 162 hospitalized patients diagnosed with COVID-19 recruited over eight months. All patients received standard treatment, but the intervention group (n = 67) was given one food supplement stick daily during their admission. After collecting the study variables, a statistical analysis was performed comparing the intervention and control groups and a multivariate analysis controlling for variables that could act as confounding factors. Results: ROC curve analysis with an area under the curve (AUC) value of 0.840 (p < 0.001; 95%CI: 0.741–0.939) of the food supplement administration vs. recovery indicated good predictive ability. Moreover, the intervention group had a shorter duration of digestive symptoms compared with the control group: 2.6 ± 1.3 vs. 4.3 ± 2.2 days (p = 0.001); patients with non-severe disease on chest X-ray had shorter hospital stays: 8.1 ± 3.9 vs. 11.6 ± 7.4 days (p = 0.007). Conclusions: In this trial, the administration of a food supplement (Gasteel Plus®) was shown to be a protective factor in the group of patients with severe COVID-19 and allowed early recovery from digestive symptoms and a shorter hospital stay in patients with a normal–mild–moderate chest X-ray at admission (ClinicalTrials.gov number, NCT04666116).

Publisher

MDPI AG

Subject

Food Science,Nutrition and Dietetics

Reference47 articles.

1. An interactive web-based dashboard to track COVID-19 in real time;Dong;Lancet Inf. Dis.,2020

2. Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia;Rosas;N. Engl. J. Med.,2021

3. SEIMC (2020, December 02). Recomendaciones SEIMC para el Manejo Clínico de Pacientes con COVID-19. Available online: https://cutt.ly/SbI6u0z.

4. Extrapulmonary manifestations of COVID-19;Gupta;Nat. Med.,2020

5. Gastrointestinal symptoms, pathophysiology, and treatment in COVID-19;Zhang;Genes Dis.,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3